CTNM Q4 2024 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

$85M

Net Income

-$15M

EPS (Diluted)

$-0.65

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$213M

Total Liabilities

$15M

Stockholders' Equity

$198M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	$85M	-$10M	+975.8%
Net Income	-$15M	-$8M	-87.5%